Details

Autor(en) / Beteiligte

• Mazzone, Peter
• Dotson, Travis
• Wahidi, Momen M
• Bernstein, Michael
• Lee, Hans J
• Feller Kopman, David
• Yarmus, Lonny
• Whitney, Duncan
• Stevenson, Christopher
• Qu, Jianghan
• Johnson, Marla
• Walsh, P. Sean
• Huang, Jing
• Lofaro, Lori R
• Bhorade, Sangeeta M
• Kennedy, Giulia C
• Spira, Avrum
• Rivera, M. Patricia
• Lim, Jun Hyeok

Titel

Clinical validation and utility of Percepta GSC for the evaluation of lung cancer

Ist Teil von

• PloS one, 2022-07, Vol.17 (7), p.e0268567-e0268567

Ort / Verlag

San Francisco: Public Library of Science

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The Percepta Genomic Sequencing Classifier (GSC) was developed to up-classify as well as down-classify the risk of malignancy for lung lesions when bronchoscopy is non-diagnostic. We evaluated the performance of Percepta GSC in risk re-classification of indeterminate lung lesions. This multicenter study included individuals who currently or formerly smoked undergoing bronchoscopy for suspected lung cancer from the AEGIS I/ II cohorts and the Percepta Registry. The classifier was measured in normal-appearing bronchial epithelium from bronchial brushings. The sensitivity, specificity, and predictive values were calculated using predefined thresholds. The ability of the classifier to decrease unnecessary invasive procedures was estimated. A set of 412 patients were included in the validation (prevalence of malignancy was 39.6%). Overall, 29% of intermediate-risk lung lesions were down-classified to low-risk with a 91.0% negative predictive value (NPV) and 12.2% of intermediate-risk lesions were up-classified to high-risk with a 65.4% positive predictive value (PPV). In addition, 54.5% of low-risk lesions were down-classified to very low risk with >99% NPV and 27.3% of high-risk lesions were up-classified to very high risk with a 91.5% PPV. If the classifier results were used in nodule management, 50% of patients with benign lesions and 29% of patients with malignant lesions undergoing additional invasive procedures could have avoided these procedures. The Percepta GSC is highly accurate as both a rule-out and rule-in test. This high accuracy of risk re-classification may lead to improved management of lung lesions.